An Effective Treatment of Severe Intractable Bleeding After Valve Repair by One Single Dose of Activated Recombinant Factor VII
- 1 August 2001
- journal article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 93 (2) , 287-289
- https://doi.org/10.1213/00000539-200108000-00009
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- REDUCED TRANSFUSION REQUIREMENTS BY RECOMBINANT FACTOR VIIa IN ORTHOTOPIC LIVER TRANSPLANTATIONTransplantation, 2001
- Management approaches to platelet-related microvascular bleeding in cardiothoracic surgeryThe Annals of Thoracic Surgery, 2000
- Overall experience with NovoSeven®Blood Coagulation & Fibrinolysis, 2000
- Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgeryBlood Coagulation & Fibrinolysis, 2000
- Anticoagulation Monitoring during Cardiac SurgeryAnesthesiology, 1999
- Reexploration for Hemorrhage Following Coronary Artery Bypass GraftingIncidence and Risk FactorsArchives of Surgery, 1998
- Clinical experience with recombinant factor VIIaBlood Coagulation & Fibrinolysis, 1998
- Platelet activity of high‐dose factor VIIa is independent of tissue factorBritish Journal of Haematology, 1997
- Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operationsThe Journal of Thoracic and Cardiovascular Surgery, 1996
- The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor.Journal of Clinical Investigation, 1993